<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of inclusion body myositis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of inclusion body myositis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of inclusion body myositis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas E Lloyd, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lisa Christopher-Stine, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ira N Targoff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sporadic inclusion body myositis (IBM) is classified, along with polymyositis, dermatomyositis, the antisynthetase syndrome, and necrotizing autoimmune myopathy, as one of the idiopathic inflammatory myopathies. However, despite some similarities, the clinicopathologic manifestations of IBM are clearly distinct from the other myositis subtypes  (<a class="graphic graphic_table graphicRef74076" href="/z/d/graphic/74076.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a>.)</p><p>The clinical manifestations and diagnosis of IBM will be reviewed here. The treatment and prognosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5164.html" rel="external">"Management of inclusion body myositis"</a>.)</p><p class="headingAnchor" id="H1178165001"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Sporadic inclusion body myositis (IBM) is a progressive muscle degenerative disease of unclear etiology [<a href="#rid1">1,2</a>]. The intense infiltration of T cells and genome-wide association studies showing linkage to the human leukocyte antigen (HLA) locus suggest that autoimmunity is a likely trigger of disease, whereas the pathological characteristics of ubiquitinated protein inclusions, onset after 45 years of age, and refractoriness to immunosuppressive therapy suggests similarities to neurodegenerative diseases [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H383299"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Inclusion body myositis (IBM) is a rare sporadic disorder with a prevalence that is estimated at 15 to 70 cases per million adults [<a href="#rid6">6-9</a>]. However, in one study of adults older than 50 years, the estimate of prevalence was as high as 180 per million adults [<a href="#rid9">9,10</a>]. Due to the high incidence of weakness complaints in older adults and the insidious onset of weakness in IBM, this disease is frequently misdiagnosed; thus, a high index of suspicion is warranted in order to make the diagnosis [<a href="#rid8">8</a>]. Indeed, it is the most common acquired idiopathic inflammatory myopathy in individuals over the age of 50 [<a href="#rid8">8</a>].</p><p>In contrast to other myositis subtypes that preferentially affect women, IBM affects men more often than women [<a href="#rid11">11</a>]. The mean age at onset of symptoms is approximately 60 years, with a range from the fourth to the ninth decade.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H771064399"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Patients with inclusion body myositis (IBM) present with the <strong>insidious onset</strong> of weakness. The average duration of symptoms before diagnosis is about five years [<a href="#rid8">8,12</a>]. The most common initial presentation is slowly progressive proximal leg weakness, with difficulty getting up out of a chair or frequent falls. In our experience, it is not unusual for patients to initially assume their symptom are secondary to aging. In some patients, the initial complaint may be weakness of grip strength, such as difficulty opening jars. Rarely, patients may present with isolated dysphagia [<a href="#rid12">12</a>].</p><p>The characteristic physical exam finding is weakness of the distal finger flexor muscles in approximately 95 percent of patients [<a href="#rid13">13,14</a>], often accompanied by "scooping" or scalloping of the medial forearm flexor compartment  (<a class="graphic graphic_picture graphicRef139581" href="/z/d/graphic/139581.html" rel="external">picture 1</a>). Though often difficult to detect on physical examination early in the course of disease, weakness and atrophy of quadriceps (knee extensor) muscles are eventually present for the majority of patients.</p><p>The following features can be seen:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with patients with polymyositis and dermatomyositis, patients with IBM are more likely to have asymmetric and distal muscle involvement and a more slowly progressive course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both proximal leg and distal arm muscle groups are usually involved. Involvement of the hip flexors, quadriceps, tibialis anterior with weakness of the ankle dorsiflexors, and forearm flexors with grip weakness are characteristic of IBM [<a href="#rid13">13-15</a>]. Facial muscles (especially muscles controlling eye closure) may be involved, but the oculomotor muscles are spared.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myalgias may accompany the weakness but are usually mild [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle atrophy progresses in parallel with the duration and severity of weakness and is greater than would be expected for the same degree of weakness in polymyositis. Deep tendon reflexes also decrease in parallel with the decline in strength.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia due to involvement of the cricopharyngeal muscle occurs in approximately half of patients. It may rarely be the presenting complaint, in some cases preceding the onset of extremity weakness by up to seven years [<a href="#rid12">12,17-19</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Laboratory abnormalities</span><span class="headingEndMark"> — </span>Muscle enzymes are typically mildly elevated early in the disease but may normalize with disease progression. Creatine kinase (CK) levels are usually less than 10 times normal [<a href="#rid20">20</a>]. An elevation of CK greater than 15 times the upper limit of normal suggests an alternative diagnosis, although rare patients with IBM may present with markedly elevated CK levels. Glucocorticoids may dramatically reduce serum CK levels in IBM, and a normalization of serum CK in the absence of an improvement of weakness is common in IBM. Measures of the acute phase response, such as the erythrocyte sedimentation rate (ESR) or the C-reactive protein (CRP), are usually normal. Myositis-specific autoantibodies are typically absent in patients with IBM; however, cytoplasmic 5'-nucleotidase 1A (cN1A) autoantibodies may help distinguish IBM from polymyositis. (See  <a class="medical medical_review" href="/z/d/html/15653.html" rel="external">"Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults", section on 'Laboratory testing and imaging'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of sporadic inclusion body myositis (IBM) generally depends upon the presence of characteristic clinical and laboratory findings which include slowly progressive muscle weakness, with early involvement of the quadriceps muscles and wrist/finger flexors, and elevated muscle enzymes. While a muscle biopsy should be performed in most patients with suspected IBM, histopathologic confirmation is not always possible, and the diagnosis may still be made based on characteristic clinical findings.</p><p>The diagnosis of IBM should be considered in patients over the age of 40 who present with progressive muscle weakness, even in the absence of an elevated serum creatine kinase (CK). If patients have proximal leg weakness and distal arm and/or leg weakness on exam, referral to a neurologist and muscle biopsy should be performed at a center with the ability to appropriately process and interpret the biopsy.</p><p>Diagnostic criteria, which have been developed for use in research, have sometimes been used to aid in making the diagnosis but have limitations when used for this purpose  (<a class="graphic graphic_table graphicRef104102" href="/z/d/graphic/104102.html" rel="external">table 2</a>). (See <a class="local">'Proposed diagnostic criteria'</a> below.)</p><p>Our approach to the diagnosis of IBM is presented below. A more general approach to the evaluation of a patient with muscle weakness is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5155.html" rel="external">"Approach to the patient with muscle weakness"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">History</span><span class="headingEndMark"> — </span>The medical history serves to identify clinical manifestations of IBM as well as identify other possible causes of muscle weakness.</p><p>We perform a thorough history with particular attention to the following symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Insidious onset of falls due to weakness of knee extensors and/or foot drop, typically in the absence of sensory complaints</p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty standing from the floor or a low chair</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of dexterity of hands or grip strength due to finger flexor weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia</p><p></p><p>We also ask about exposure to a variety of prescription and illicit drugs that may cause myopathy, myositis, neuropathy, or other disorders that cause muscle weakness. Among the drug exposures that should be specifically sought are antimalarial drugs (eg, <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>), <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, glucocorticoids, cholesterol-lowering drugs (eg, HMG-CoA reductase inhibitors [statins]), alcohol, and cocaine. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a>.)</p><p>Symptoms of associated conditions should be reviewed given that as many as 15 percent of IBM patients have underlying autoimmune disorders such as systemic lupus erythematosus (SLE), Sjögren's disease, systemic sclerosis (scleroderma), Hashimoto thyroiditis, variable immunoglobulin deficiency, sarcoidosis, and idiopathic thrombocytopenia purpura [<a href="#rid21">21,22</a>]. However, unlike other inflammatory myopathies such as polymyositis or dermatomyositis, IBM is not associated with myocarditis, interstitial lung disease, or an increased risk of malignancy.</p><p>A careful family history should be taken, as some hereditary myopathies such as Limb-Girdle Muscular Dystrophy and hereditary IBM may have proximal and distal weakness as well as rimmed vacuoles and/or inflammation on muscle biopsy and may be misdiagnosed as IBM. (See  <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">"Limb-girdle muscular dystrophy"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination helps to determine the distribution of muscle weakness and atrophy. Findings of quadriceps (ie, knee extensor) and forearm flexor (ie, wrist and finger flexor) muscle weakness and wasting are clinical hallmarks of IBM [<a href="#rid23">23</a>]. Many patients also have significant hip flexion weakness and are typically unable to stand from a chair without pushing off with their arms. With severe quadriceps weakness, patients may walk with the leg hyperextended (genu recurvatum). To detect subtle weakness of distal finger flexion (typically the earliest exam finding), the clinician should isolate and specifically examine flexion at the distal interphalangeal (DIP) joint. Other muscles that are commonly affected are orbicularis oculi (leading to weakness with eye closure), triceps (weakness with arm extension), and tibialis anterior (leading to foot drop) [<a href="#rid24">24</a>].</p><p>While many patients with IBM present with symmetric and proximal muscle weakness suggestive of polymyositis, the finding of more distal, asymmetric involvement with finger and wrist flexor weakness greater than deltoid weakness and knee extensor weakness greater than hip flexor weakness would be more typical of IBM.</p><p class="headingAnchor" id="H10"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>There is no definitive diagnostic laboratory test for IBM. Mild to moderate elevations of plasma muscle enzyme levels (serum CK less than 10-fold higher than normal) are common with IBM, while levels greater than 15-fold often suggest other causes.</p><p>The purpose of laboratory testing is primarily to exclude an alternative diagnosis that could lead to weakness and to look for associated conditions. Laboratory tests that are performed in the evaluation of patients with muscle weakness include serum electrolytes, calcium, magnesium, phosphate, creatine kinase, aldolase, lactate dehydrogenase, serum aminotransferases, and thyroid-stimulating hormone. An elevated alkaline phosphatase level should prompt evaluation for Paget disease, which can be seen in hereditary IBM. (See  <a class="medical medical_review" href="/z/d/html/5601.html" rel="external">"Clinical manifestations and diagnosis of Paget disease of bone"</a>.)</p><p>Testing for autoantibodies directed against cytoplasmic 5'-nucleotidase 1A (cN1A) may be helpful for distinguishing IBM from other forms of myositis [<a href="#rid25">25,26</a>]. A study evaluated the diagnostic performance of immunoglobulin M (IgM), IgA, and IgG anti-cN1A serum antibodies detected by enzyme-linked immunosorbent assay (ELISA) in 205 patients with muscle disease, 50 of whom had IBM [<a href="#rid27">27</a>]. A combination assay of all three autoantibody levels resulted in a sensitivity and specificity of 76 and 91 percent, respectively. However, anti-cN1A antibodies are also detected in about 20 percent of patients with SLE and Sjögren's disease in the absence of muscle disease [<a href="#rid28">28,29</a>]. Laboratory testing is commercially available [<a href="#rid30">30</a>], and we recommend testing in diagnostically challenging cases.</p><p>There is an association of IBM with some autoimmune diseases, such as Sjögren's disease and sarcoidosis, as well as with some lymphoproliferative disorders such as T cell large granular lymphocytic leukemia [<a href="#rid31">31</a>]. In addition, IBM has been observed in patients with chronic viral infections such as HIV and Hepatitis C [<a href="#rid32">32,33</a>]. As such, screening laboratory testing for antinuclear antibodies (ANA), anti-Ro(SSA), anti-La(SSB), serum immunofixation, human immunodeficiency virus (HIV), and hepatitis C should also be obtained.</p><p class="headingAnchor" id="H2477710012"><span class="h2">Electromyography</span><span class="headingEndMark"> — </span>Electromyography (EMG) and nerve conduction studies are extremely useful tests in all patients with suspected muscle disease. EMG in IBM typically reveals an "irritable myopathy" with increased insertional activity, fibrillations, positive waves, and early recruitment of short-duration, small-amplitude polyphasic motor unit action potentials (MUAPs). Fasciculations are not observed. These findings strongly suggest a diagnosis of inflammatory myopathy. In some muscles, EMG may show reduced recruitment and a mixture of short and long duration, small- and large-amplitude polyphasic MUAPs. This mixed pattern of myopathic and "neurogenic"-appearing units is more typical of IBM than polymyositis or dermatomyositis [<a href="#rid16">16,20,34,35</a>]. Nerve conduction studies are usually normal, but may show a concomitant peripheral neuropathy in some cases. (See  <a class="medical medical_review" href="/z/d/html/5145.html" rel="external">"Overview of electromyography"</a> and  <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">"Overview of nerve conduction studies"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is useful in evaluating patients with suspected myopathy including IBM who present with equivocal weakness and/or mildly elevated muscle enzymes. MRI has the advantage of sampling wide areas of muscle as opposed to muscle biopsy that may miss a diagnosis due to sampling error. While there are no findings on MRI studies that are diagnostic for IBM, there are some disease-specific patterns of muscle involvement that may support the diagnosis and help distinguish IBM from polymyositis [<a href="#rid36">36-38</a>]. For example, MRI of the thigh typically shows edema, atrophy, and fatty replacement of the anterior compartment with relative sparing of the medial and posterior compartments.</p><p class="headingAnchor" id="H12"><span class="h2">Muscle biopsy</span><span class="headingEndMark"> — </span>Muscle biopsy may be diagnostic in IBM and in many cases can distinguish it from polymyositis and other muscle diseases, which is not always possible on a clinical basis. We biopsy muscles that are only moderately weak (4 or 4+ on MRC scale) and prefer biceps or quadriceps muscles. MRI and EMG may be useful in guiding the selection of a muscle for biopsy, as the diagnostic yield for biopsy is low in muscles with extensive atrophy and/or fatty replacement. However, in some cases, the muscle biopsy in IBM is nonspecific and the diagnosis depends on a combination of clinical findings and a biopsy consistent with IBM.</p><p>The histologic features on muscle biopsy associated with IBM include [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mononuclear cell infiltration of non-necrotic muscle fibers. The infiltrate is predominantly CD8+ T lymphocytes and macrophages. Major histocompatibility complex (MHC)-I is upregulated on immunostaining. These are histologic features of an inflammatory myopathy and are also seen in polymyositis [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoplasmic "rimmed" vacuoles that are red-rimmed on modified trichrome stain and blue-rimmed on hematoxylin and eosin (H&amp;E). It is important to note, however, that as many as 20 to 30 percent of any given muscle biopsy in IBM may lack the canonical rimmed vacuoles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myofiber degeneration, regeneration, and necrosis may be seen. Variability of fiber size with scattered atrophic fibers is common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abundant "COX [cytochrome oxidase]-negative" fibers suggestive of mitochondrial abnormalities is common [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On electron microscopy, the inclusions are shown to consist of 15 to 18 nm tubulofilaments that are not present in other inflammatory myopathies. These inclusions can be seen in the sarcoplasm and within myonuclei.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amyloid deposits in vacuolated fibers identified by Congo red staining are occasionally observed [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunostaining for p62 and TDP-43 labeled characteristic protein aggregates. These inclusions are much more common than amyloid, and the presence of fibers on biopsy that contain these protein aggregates increases diagnostic certainty for IBM [<a href="#rid42">42-44</a>].</p><p></p><p>The commonly used Griggs criteria require the presence of rimmed vacuoles, mononuclear inflammatory cells invading non-necrotic muscle fibers, and the presence of either amyloid deposits or tubulofilaments by electron microscopy for pathologically definite IBM is highly specific when all three components are present, but lacks sensitivity and is rarely used clinically [<a href="#rid45">45</a>]. There may be sampling variability, and not all of the histologic features may be present in early disease but may appear on subsequent biopsies. Furthermore, electron microscopy of muscle tissue is only performed routinely at a few specialized centers.</p><p>Immunohistologic and electron-microscopic evaluation of the tissue require freshly frozen muscle and special fixatives. A discussion of the technical aspects of muscle biopsy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15653.html" rel="external">"Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults", section on 'Muscle biopsy'</a>.)</p><p>The best diagnostic information can be expected from a laboratory that frequently processes muscle biopsy specimens and whose staff is provided with detailed clinical information. This may be facilitated by a discussion between the clinician requesting the biopsy, the surgeon, and pathologist prior to the procedure, or by referral of the patient to a center with the necessary laboratory facilities.</p><p class="headingAnchor" id="H771064528"><span class="h1">PROPOSED DIAGNOSTIC CRITERIA</span><span class="headingEndMark"> — </span>Several diagnostic criteria have been developed based on expert opinion and consensus groups [<a href="#rid45">45-48</a>]. While these diagnostic criteria are essential for the purposes of research and classifying patients for clinical trials, their clinical use is often limited by a lack of sensitivity [<a href="#rid13">13</a>]. A relatively simple and clinically useful set of criteria has been proposed that has 90 percent sensitivity and 96 percent specificity among 371 patients with muscle diseases [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Finger flexor or quadriceps weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Endomysial inflammation</p><p class="bulletIndent1"><span class="glyph">●</span>Invasion of nonnecrotic muscle fibers or rimmed vacuoles</p><p></p><p>The proposed European Neuromuscular Centre (ENMC) 2011 "Clinically Defined" diagnostic criteria diagnose inclusion body myositis (IBM) with &gt;99 percent specificity but a sensitivity of only 57 percent (ie, approximately 43 percent of IBM patients seen in routine clinical practice will not satisfy these definite criteria, typically due to hip flexor weakness &gt; knee extensor weakness)  (<a class="graphic graphic_table graphicRef104102" href="/z/d/graphic/104102.html" rel="external">table 2</a>) [<a href="#rid13">13,49</a>]. These criteria are currently being used in clinical trials.</p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>While it is beyond the scope of this review to provide a comprehensive list of all possible alternative causes of a myopathy  (<a class="graphic graphic_table graphicRef70008" href="/z/d/graphic/70008.html" rel="external">table 3</a>), we present several disorders that can resemble inclusion body myositis (IBM) here:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymyositis</strong> – IBM and polymyositis can in some cases be difficult to distinguish clinically or by muscle biopsy. In the absence of rimmed vacuoles or protein aggregates found on immunostaining or electron microscopy, the muscle biopsy in IBM may only demonstrate endomysial inflammation that closely resembles that seen in polymyositis. Combining clinical and histologic findings increases the chance of a correct diagnosis. The lack of response to high-dose steroids should lead to a reevaluation of the diagnosis of polymyositis, which is increasingly recognized as a rare entity [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/15653.html" rel="external">"Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditable myopathies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary inclusion body myositis (hIBM) – These patients present with slowly progressive muscle weakness (variously labeled familial distal myopathy, autosomal recessive hereditary inclusion body myopathies, and distal myopathy with rimmed vacuole formation), usually with marked distal muscle group involvement, and the muscle biopsy shows a vacuolar myopathy with inclusions [<a href="#rid45">45,51-53</a>]. In contrast to sporadic IBM, the onset of weakness is usually in early adulthood and spares quadriceps muscles. The family history and a paucity of inflammation on histologic examination help to distinguish these rare heritable disorders from sporadic IBM.</p><p></p><p class="bulletIndent2">The most common cause of hIBM is "GNE myopathy" (hIBM2), an autosomal recessive form of inclusion body myopathy caused by mutations in the gene for UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) [<a href="#rid53">53,54</a>]. Some endomysial inflammation was noted in two patients with this disorder, both of whom had compound heterozygous mutations in their GNE genes [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multisystem proteinopathy (MSP) – With the advent of whole exome sequencing, it is becoming increasingly evident that many hIBM families have a pleiotropic degenerative disorder that may affect muscle, bone, and the nervous system [<a href="#rid56">56</a>]. The originally described phenotype of autosomal dominantly inherited IBM with Paget disease of bone (PDB) and frontotemporal dementia (IBMPFD) caused by mutations in the gene for valosin-containing protein (VCP) [<a href="#rid57">57,58</a>], has been expanded to include neurodegeneration of motor neurons, peripheral nerves, and other neuronal subtypes [<a href="#rid56">56</a>]. Furthermore, mutations in other genes including SQSTM1/p62, hnRNPA1, hnRNPA2B1, and Matrin-3 can cause a similar MSP syndrome. That similar protein aggregates and rimmed vacuoles are observed in muscle in these patients with a multisystem degenerative disease suggests an intriguing pathophysiologic link between sporadic IBM and neurodegenerative diseases. The genetic, clinical, and histological features of these rare diseases are just being described, but can usually be distinguished from sporadic IBM by the absence of inflammation on muscle biopsy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Muscular dystrophy – Other inherited myopathies that variably show rimmed vacuoles and/or inflammation on muscle biopsy can occasionally be misdiagnosed as IBM, in particular oculopharyngeal muscular dystrophy (OPMD), fascioscapulohumeral dystrophy (FSHD), and limb girdle muscular dystrophy (LGMD), distal myopathies, and myofibrillar myopathies. The correct diagnosis can usually be suspected based on the earlier age of onset, the pattern of weakness, and/or family history. Diagnosis is confirmed by genetic testing. (See  <a class="medical medical_review" href="/z/d/html/6180.html" rel="external">"Oculopharyngeal, distal, and congenital muscular dystrophies"</a> and  <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">"Limb-girdle muscular dystrophy"</a> and  <a class="medical medical_review" href="/z/d/html/87096.html" rel="external">"Facioscapulohumeral muscular dystrophy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced myopathies</strong> – Vacuolar changes are also present in drug-induced myopathy due to <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>. The more acute presentation and drug history differentiate these conditions from IBM. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amyotrophic lateral sclerosis</strong> – Patients with IBM who have predominantly distal or asymmetric involvement may resemble motor neuron disease or peripheral neuropathies with predominantly lower motor neuron involvement. Electrophysiologic testing and muscle biopsy may be necessary to establish the correct diagnosis. Electromyography (EMG) of the forearm flexor muscles may be particularly useful in distinguishing the primarily myopathic features of IBM from the neurogenic features of ALS [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/5138.html" rel="external">"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease"</a>.)</p><p></p><p class="headingAnchor" id="H2798241463"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/131149.html" rel="external">"Society guideline links: Inclusion body myositis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/578.html" rel="external">"Patient education: Polymyositis, dermatomyositis, and other forms of idiopathic inflammatory myopathy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Inclusion body myositis (IBM) is a rare sporadic disorder in adults that causes muscle weakness with an insidious onset. The distribution of weakness can be either symmetric or asymmetric, and both proximal and distal muscle groups can be involved. Dysphagia occurs in about one-third of patients. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle enzymes are typically normal or mildly elevated in IBM, with creatine kinase (CK) levels generally being less than 10 times normal. (See <a class="local">'Laboratory abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of sporadic IBM depends upon the presence of characteristic clinical and laboratory findings which include a slowly progressive muscle weakness with early involvement of the quadriceps muscles and wrist/finger flexors, and elevated muscle enzymes. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A muscle biopsy should be performed in patients with suspected IBM. However, histopathologic confirmation is not always possible, and the diagnosis may still be made based on characteristic clinical findings. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle biopsy findings that are highly specific for IBM include the presence of rimmed vacuoles, mononuclear cell inflammatory infiltrate of non-necrotic muscle fibers, and the presence of either amyloid deposits or tubulofilaments by electron microscopy. (See <a class="local">'Muscle biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Findings on electromyography (EMG) and magnetic resonance imaging (MRI) may also help support the diagnosis of IBM when present. EMG typically reveals an "irritable myopathy" with increased insertional activity, fibrillations, positive waves, and early recruitment of short-duration, small-amplitude polyphasic motor unit action potentials (MUAPs). MRI abnormalities in IBM tend to be localized to the anterior muscle groups. (See <a class="local">'Magnetic resonance imaging'</a> above and <a class="local">'Electromyography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis of IBM includes other idiopathic inflammatory myopathies (eg, dermatomyositis and polymyositis), hereditable inclusion body myopathies (hIBM), drug-induced myopathies, and amyotrophic lateral sclerosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H4147986438"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Marc L Miller, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weihl CC, Mammen AL. Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy. Neuropathol Appl Neurobiol 2017; 43:82.</a></li><li><a class="nounderline abstract_t">McLeish E, Slater N, Sooda A, et al. Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity. Best Pract Res Clin Rheumatol 2022; 36:101761.</a></li><li><a class="nounderline abstract_t">Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 2019; 15:257.</a></li><li><a class="nounderline abstract_t">Britson KA, Yang SY, Lloyd TE. New Developments in the Genetics of Inclusion Body Myositis. Curr Rheumatol Rep 2018; 20:26.</a></li><li><a class="nounderline abstract_t">Britson KA, Ling JP, Braunstein KE, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med 2022; 14:eabi9196.</a></li><li><a class="nounderline abstract_t">Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55:1385.</a></li><li><a class="nounderline abstract_t">Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000; 23:970.</a></li><li><a class="nounderline abstract_t">Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008; 15:1350.</a></li><li><a class="nounderline abstract_t">Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008; 35:445.</a></li><li><a class="nounderline abstract_t">Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study. Neurology 2021; 96:e2653.</a></li><li><a class="nounderline abstract_t">Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin 2014; 32:629.</a></li><li><a class="nounderline abstract_t">Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134:3176.</a></li><li><a class="nounderline abstract_t">Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014; 83:426.</a></li><li><a class="nounderline abstract_t">Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134:3167.</a></li><li><a class="nounderline abstract_t">Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40:581.</a></li><li><a class="nounderline abstract_t">Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993; 71:351.</a></li><li><a class="nounderline abstract_t">Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001; 80:320.</a></li><li><a class="nounderline abstract_t">Wintzen AR, Bots GT, de Bakker HM, et al. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry 1988; 51:1542.</a></li><li><a class="nounderline abstract_t">Riminton DS, Chambers ST, Parkin PJ, et al. Inclusion body myositis presenting solely as dysphagia. Neurology 1993; 43:1241.</a></li><li><a class="nounderline abstract_t">Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112 ( Pt 3):727.</a></li><li><a class="nounderline abstract_t">Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998; 21:115.</a></li><li><a class="nounderline abstract_t">Vattemi G, Tonin P, Marini M, et al. Sarcoidosis and inclusion body myositis. Rheumatology (Oxford) 2008; 47:1433.</a></li><li><a class="nounderline abstract_t">Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80:1186.</a></li><li><a class="nounderline abstract_t">Engel WK, Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 2006; 66:S20.</a></li><li><a class="nounderline abstract_t">Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73:408.</a></li><li><a class="nounderline abstract_t">Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73:397.</a></li><li><a class="nounderline abstract_t">Greenberg SA. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve 2014; 50:488.</a></li><li><a class="nounderline abstract_t">Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken) 2016; 68:66.</a></li><li><a class="nounderline abstract_t">Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2016; 75:696.</a></li><li class="breakAll">http://neuromuscular.wustl.edu/over/labdis.html (Accessed on October 01, 2015).</li><li><a class="nounderline abstract_t">Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 2016; 139:1348.</a></li><li><a class="nounderline abstract_t">Uruha A, Noguchi S, Hayashi YK, et al. Hepatitis C virus infection in inclusion body myositis: A case-control study. Neurology 2016; 86:211.</a></li><li><a class="nounderline abstract_t">Lloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 2017; 88:1454.</a></li><li><a class="nounderline abstract_t">Kula RW, Sawchak JA, Sher JH. Inclusion body myositis. Curr Opin Rheumatol 1989; 1:460.</a></li><li><a class="nounderline abstract_t">Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19:1385.</a></li><li><a class="nounderline abstract_t">Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29:1897.</a></li><li><a class="nounderline abstract_t">Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011; 50:1153.</a></li><li><a class="nounderline abstract_t">Tasca G, Monforte M, De Fino C, et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 2015; 52:956.</a></li><li><a class="nounderline abstract_t">Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16:209.</a></li><li><a class="nounderline abstract_t">Lindgren U, Roos S, Hedberg Oldfors C, et al. Mitochondrial pathology in inclusion body myositis. Neuromuscul Disord 2015; 25:281.</a></li><li><a class="nounderline abstract_t">Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991; 48:1229.</a></li><li><a class="nounderline abstract_t">Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40:19.</a></li><li><a class="nounderline abstract_t">Hiniker A, Daniels BH, Lee HS, Margeta M. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun 2013; 1:29.</a></li><li><a class="nounderline abstract_t">Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open 2014; 4:e004552.</a></li><li><a class="nounderline abstract_t">Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Mitsumoto H, Chou SM. Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum 1987; 30:397.</a></li><li><a class="nounderline abstract_t">Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6:620.</a></li><li><a class="nounderline abstract_t">Dalakas MC. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006; 2:437.</a></li><li><a class="nounderline abstract_t">Rose MR, ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013; 23:1044.</a></li><li><a class="nounderline abstract_t">van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61:316.</a></li><li><a class="nounderline abstract_t">Askanas V. New developments in hereditary inclusion body myopathies. Ann Neurol 1997; 41:421.</a></li><li><a class="nounderline abstract_t">Ranque-Francois B, Maisonobe T, Dion E, et al. Familial inflammatory inclusion body myositis. Ann Rheum Dis 2005; 64:634.</a></li><li><a class="nounderline abstract_t">Nishino I, Noguchi S, Murayama K, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 2002; 59:1689.</a></li><li><a class="nounderline abstract_t">Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001; 29:83.</a></li><li><a class="nounderline abstract_t">Yabe I, Higashi T, Kikuchi S, et al. GNE mutations causing distal myopathy with rimmed vacuoles with inflammation. Neurology 2003; 61:384.</a></li><li><a class="nounderline abstract_t">Taylor JP. Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology 2015; 85:658.</a></li><li><a class="nounderline abstract_t">Kimonis VE, Kovach MJ, Waggoner B, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med 2000; 2:232.</a></li><li><a class="nounderline abstract_t">Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36:377.</a></li><li><a class="nounderline abstract_t">Hokkoku K, Sonoo M, Higashihara M, et al. Electromyographs of the flexor digitorum profundus muscle are useful for the diagnosis of inclusion body myositis. Muscle Nerve 2012; 46:181.</a></li></ol></div><div id="topicVersionRevision">Topic 5163 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28111778" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35760741" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30837708" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inclusion body myositis: clinical features and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29611059" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New Developments in the Genetics of Inclusion Body Myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35044790" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087787" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10842277" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of sporadic inclusion body myositis in Western Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18815046" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18203321" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33879596" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037082" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21994327" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term observational study of sporadic inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975859" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation and construction of diagnostic criteria for inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21908393" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8871577" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inclusion body myositis: clinical and pathological boundaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8389626" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inclusion body myositis: clinical and histopathological features of 36 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552086" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2851642" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dysphagia in inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170574" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Inclusion body myositis presenting solely as dysphagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2543478" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inclusion body myositis. Observations in 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427231" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18611922" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sarcoidosis and inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19864656" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inclusion body myositis: old and new concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16432141" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inclusion-body myositis: clinical, diagnostic, and pathologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23596012" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460448" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24752512" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892010" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714931" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714931" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26920676" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of inclusion body myositis with T cell large granular lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26683644" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepatitis C virus infection in inclusion body myositis: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283597" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2562009" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1331441" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inclusion body myositis: analysis of 32 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233884" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288962" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25808807" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6089646" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638290" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mitochondrial pathology in inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1668977" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19533646" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252466" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24776709" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486861" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Inclusion body myositis and myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3034295" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Inclusion body myositis presenting as treatment-resistant polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582362" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932602" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268584" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913190" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Polymyositis: an overdiagnosed entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124797" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New developments in hereditary inclusion body myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769920" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Familial inflammatory inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473753" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528398" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913203" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : GNE mutations causing distal myopathy with rimmed vacuoles with inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26208960" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11252708" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034582" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806366" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Electromyographs of the flexor digitorum profundus muscle are useful for the diagnosis of inclusion body myositis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
